Evidence For Healthcare Improvement

BETTER HEALTH FOR ALL AMERICANS THROUGH SUSTAINABLE ACCESS TO HIGH-VALUE HEALTH CARE.

ICER'S PROGRAM TO EVALUATE NEW TECHNOLOGIES, INCLUDING NEW DRUGS AT OR NEAR THE TIME OF FDA APPROVAL, PROVIDES AN INDEPENDENT ANALYSIS OF THE COMPARATIVE EFFECTIVENESS OF NEW TECHNOLOGIES, ALONG WITH AN ASSOCIATED HEALTH-BENEFIT PRICE BENCHMARK, WITH THE OBJECTIVE OF HELPING DECISION-MAKERS UNDERSTAND AND APPLY EVIDENCE TO IMPROVE VALUE THROUGHOUT THE HEALTH CARE SYSTEM. THE ROBUST RESEARCH CONDUCTED TO PRODUCE REPORTS FOR THE TECHNOLOGY ASSESSMENT PROGRAM IS COMPLEMENTED BY AN EXTENSIVE PATIENT AND STAKEHOLDER ENGAGEMENT PROGRAM THAT ENSURES THAT THE EXPERIENCE OF PATIENTS AND THEIR FAMILIES ARE AT THE CENTER OF THE WORK. THE REPORTS OF THE TECHNOLOGY ASSESSMENT PROGRAM ARE VETTED THROUGH THREE REGIONAL COLLABORATIVES OF INDEPENDENT EXPERTS IN THE EVALUATION AND APPLICATION OF EVIDENCE: THE CALIFORNIA TECHNOLOGY ASSESSMENT FORUM (CTAF), THE MIDWEST COMPARATIVE EFFECTIVENESS PUBLIC ADVISORY COUNCIL (MIDWEST CEPAC), AND THE NEW ENGLAND COMPARATIVE EFFECTIVENESS PUBLIC ADVISORY COUNCIL (NEW ENGLAND CEPAC). FOR EACH PANEL, INDEPENDENT CLINICIANS, METHODOLOGISTS, AND PUBLIC REPRESENTATIVES CONVENE SEVERAL TIMES A YEAR AT PUBLIC MEETINGS TO REVIEW OBJECTIVE EVIDENCE REPORTS PRODUCED BY ICER AND TO DEVELOP RECOMMENDATIONS FOR HOW STAKEHOLDERS CAN APPLY EVIDENCE TO IMPROVE THE QUALITY AND VALUE OF HEALTH CARE. ALL THREE PANELS DIRECTLY ENGAGE CLINICIANS, PATIENTS, AND PAYORS DURING THESE PUBLIC MEETINGS TO DISCUSS APPLICATION OF THE EVIDENCE FOR CLINICAL DECISION-MAKING, BENEFIT DESIGN, AND PATIENT AND CLINICIAN TOOLS TO IMPROVE CLINICAL CARE AND PATIENT OUTCOMES.

ICER ANALYTICS IS A NEW CLOUD-BASED PLATFORM THAT FACILITATES THE USE OF ICER'S EVIDENCE REPORTS AND UNDERLYING ANALYSES TO HELP ALL AMERICANS ACHIEVE SUSTAINABLE ACCESS TO HIGH-VALUE CARE. AVAILABLE ON A SUBSCRIPTION BASIS, THE PLATFORM PROVIDES PHARMACEUTICAL MANUFACTURERS, PRIVATE AND PUBLIC PAYORS, CLINICIANS, PATIENTS, AND OTHER STAKEHOLDERS, WITH A SUITE OF TOOLS THAT STREAMLINE INTERPRETATION OF ICER'S ANALYSES DIRECTLY FROM THE SOURCE ALL DESIGNED TO SUPPORT INTEGRATION INTO USERS' OWN PRICING, REIMBURSEMENT, AND CLINICAL WORK. ICER ANALYTICS SUBSCRIBERS HAVE ACCESS TO ICER'S PRICE BENCHMARKS, COST-EFFECTIVENESS RESULTS, COMPARATIVE CLINICAL EFFECTIVENESS JUDGMENTS, POLICY RECOMMENDATIONS, AND ECONOMIC MODELS WITHIN TWO PRIMARY TOOLS THE EVIDENCE COMPENDIUM AND THE INTERACTIVE MODELER.

THE POLICY LEADERSHIP FORUM ("PLF") WAS LAUNCHED TO GIVE A SELECT NUMBER OF LEADING HEALTH CARE ORGANIZATIONS A UNIQUE OPPORTUNITY TO SHAPE THE FUTURE OF EVIDENCE AND COVERAGE POLICY IN THE UNITED STATES. THE TENSION BETWEEN INNOVATION AND HEALTH CARE COSTS CONTINUES TO FOCUS CRITICAL ATTENTION ON HOW EVIDENCE WILL BE DEVELOPED BY MANUFACTURERS AND HOW IT WILL BE INTERPRETED BY PAYORS IN MAKING COVERAGE DECISIONS. BENEFITING FROM ICER'S EXPERIENCE AS A LEADER IN HEALTH TECHNOLOGY ASSESSMENT, AND ITS UNIQUE ABILITY TO SERVE AS AN ENGAGED, OBJECTIVE CONVENER AND MODERATOR, PLF BRINGS TOGETHER A SMALL, INFLUENTIAL GROUP OF EVIDENCE LEADERS FROM INSURERS, PHARMACY BENEFIT MANAGEMENT FIRMS, HEALTH TECHNOLOGY ASSESSMENT GROUPS, AND LIFE SCIENCE COMPANIES TO ADDRESS KEY CONTROVERSIES IN EVIDENCE METHODS AND POLICY. WORKING TOGETHER IN A BALANCED, NONADVERSARIAL ENVIRONMENT, PLF MEMBERS GAIN THE SKILLS AND INSIGHTS IN EVIDENCE POLICY NECESSARY TO STRENGTHEN THEIR COMPETITIVE POSITION IN THE MARKETPLACE.